These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1699 related articles for article (PubMed ID: 18263627)

  • 1. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
    Raji CA; Becker JT; Tsopelas ND; Price JC; Mathis CA; Saxton JA; Lopresti BJ; Hoge JA; Ziolko SK; DeKosky ST; Klunk WE
    J Neurosci Methods; 2008 Jul; 172(2):277-82. PubMed ID: 18582948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
    Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.
    Wirth M; Madison CM; Rabinovici GD; Oh H; Landau SM; Jagust WJ
    J Neurosci; 2013 Mar; 33(13):5553-63. PubMed ID: 23536070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
    Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of [
    Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
    Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
    Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
    Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.